SELLAS Life Sciences Group, Inc. has announced its financial results for the third quarter of 2026, showcasing significant advancements in its clinical trials and a robust cash position. This update is crucial as it reflects the company's ongoing commitment to developing innovative therapies for cancer, particularly acute myeloid leukemia (AML).

On November 12, 2026, SELLAS Life Sciences issued a press release detailing its financial performance for the quarter ending September 30, 2026. The report indicates that the company is making strides in its clinical programs, especially with the Phase 3 REGAL trial of its lead candidate, Galinpepimut-S (GPS). The trial is nearing an important milestone, with topline primary endpoint results expected to be reported this month.

Background

SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for a range of cancer indications. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations. SELLAS trades on the Nasdaq under the ticker symbol SLS.

What the Filing Says

According to the filing, “We continue to execute across both of our clinical programs as we approach several important milestones,” stated Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS Life Sciences. The company reported having $134.7 million in cash and cash equivalents as of September 30, 2026, which positions it well to advance its clinical programs.

Notably, the REGAL trial is focused on AML patients who have achieved complete remission following second-line salvage therapy. The announcement of the 80th event in the trial has triggered a database lock and data review procedures, with results expected soon. Additionally, the company is progressing in its Phase 2 trial of tambiciclib (SLS009), with preliminary data anticipated in the fourth quarter of 2026.

Impact

This update is significant for various stakeholders, including investors, healthcare professionals, and patients. The results from the REGAL trial could potentially transform treatment options for AML patients, particularly those in second complete remission. The pharmaceutical industry, especially companies involved in cancer therapies, will be closely watching SELLAS's progress, as successful outcomes may influence market strategies and competition.

What's Next

SELLAS Life Sciences is expected to release the topline results from the REGAL trial later this month. The filing does not specify any upcoming votes or additional filings related to this announcement.